1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
Key Points
Novo Nordisk is leading the race to get an oral weight loss GLP-1 drug approved.
It needs to ensure it has addressed production quality and supply chain issues.
Oral Wegovy is demonstrating superiority over Eli Lilly's comparable candidate.
Novo Nordisk (NYSE: NVO) has come under pressure over the past year (down almost 52%) as profit assumptions for its weight loss drug Wegovy have been pared back. A combination of high-profile quality control issues, supply chain bottlenecks , and increasing competition from Eli Lilly's (NYSE: LLY) Zepbound have dramatically reset investor expectations.
Still, the company looks set to turn the tide in the battle over weight loss drugs. Here's why.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
Novo Nordisk and the oral GLP-1 weight loss market
There are two key reasons why Novo Nordisk can emerge victorious in the race to commercialize an oral version of a GLP-1 weight loss drug -- the currently approved drugs are injectables.
First, it's the first in line to be approved, with a Food and Drug Administration (FDA) decision due in the fourth quarter of this year. In contrast, Eli Lilly plans to submit oral weight loss drug orforglipron for regulatory review in obesity in late 2025, and for type 2 diabetes in late 2026.
Second, based on the current data, Novo Nordisk's oral Wegovy appears to have the edge over orforglipron in obesity. The company recently published results for the phase 3 (OASIS-4) trial, which demonstrated an efficacy and safety advantage over Eli Lilly's orforglipron.
|
Company |
Drug (oral for weight loss) |
Trial |
Discontinuation rate due to adverse effects (treated) |
Discontinuation rate due to adverse effects (placebo) |
Body weight change |
|---|---|---|---|---|---|
|
Novo Nordisk |
semaglutide (oral Wegovy) |
OASIS-4 |
6.9% |
5.9% |
16.6% |
|
Eli Lilly |
orforglipron |
ATTAIN-1 |
10.3%* |
2.6% |
12.4%* |
Data source: Eli Lilly, Novo Nordisk presentations. *At the highest dosage.
Where next for Novo Nordisk?
All told, if Novo Nordisk can secure oral Wegovy approval first and continue to demonstrate superiority in the lab, while avoiding any operational mishaps, the company looks well-positioned to prosper in 2026.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $657,110!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,093,751!*
Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of September 22, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Related Articles
Carnival’s Q3 2025 Earnings Preview: Can Strong Demand and Celebration Key Drive Valuation Higher?
TradingKey - Fueled by robust consumer demand for cruise travel, Carnival has hit all-time highs in several key metrics, including revenue, yield, and customer deposits. Its stock has performed strongly in 2025, with a year-to-date gain exceeding 20% and a nearly 70% increase over the past 12 months
TikTok US Deal: Business before Politics
TradingKey - Just like how Facebook took over the world by storm in the late 2000s, TikTok took over the world in the early 2020s. The catalyst for TikTok’s rise was the COVID-19 pandemic, which kept people at home with little to do
U.S. August PCE Preview: Four-Run PCE Bounce Challenges the Fed’s Three-Cut Plan
TradingKey - The U.S. Bureau of Economic Analysis (BEA) will release the August Personal Consumption Expenditures (PCE) Price Index on Friday, September 26, with markets closely watching how much tariff pass-through effects have influenced inflation.
Fed Officials Cool Hopes for Rate Cuts.Will Gold Price Rally Toward the $4,000 Threshold?
TradingKey - Since the Federal Reserve announced a 25-basis-point rate cut last week, market sentiment on future easing has turned divergent, with several Fed officials recently tempering expectations for additional cuts.
U.S. August PCE: Inflation Remains the Market's Greatest Risk
Our baseline forecast anticipates sustained asset price increases. However, if inflation surpasses market expectations in the coming months, it could hinder further rate cuts and pose the greatest risk to financial markets.
